For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Gw Pharma Limited

USPTO Granted Patents = 66

CIPO Patents = 12

EPO Patents = 39

Trademarks = 11

Forward Citations = 2,521

Loading Chart...

Loading Chart...

75 inventors (with patents filed for the assignee):

Geoffrey W Guy (32 out of 72 patents)

Brian Anthony Whittle (17 out of 28 patents)

Stephen Wright (17 out of 60 patents)

4. Alice Mead (10 out of 12 patents)

5. Colin Stott (9 out of 17 patents)

6. Orrin Devinsky (8 out of 27 patents)

7. Gary Stephens (8 out of 11 patents)

8. Claire Williams (8 out of 12 patents)

9. Rajiv Bobby Dave (7 out of 10 patents)

10. Tetsuro Kikuchi (6 out of 25 patents)

11. David Victor Downs (5 out of 5 patents)

12. Vincenzo Di Marzo (4 out of 13 patents)

13. Benjamin Whalley (4 out of 20 patents)

14. Thomas Hill (4 out of 4 patents)

15. Ben Whalley (4 out of 4 patents)

Core Competencies:

Phytocannabinoids

Cannabidiol

Cannabidivarin

Cannabinoid Extracts

Neurodegenerative Diseases

Inflammatory Skin Diseases

Cancer Treatment

Epilepsy Treatment

Neuropathic Pain

Tetrahydrocannabinol

Active Pharmaceutical Ingredients

Anti-Tumoural Effects

66 patents: Sort by Forward Citations

1. 12121499 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2024-10-22),

2. 12023305 - Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy (2024-07-02),

3. 11413266 - Use of cannabinoids in the treatment of inflammatory skin diseases (2022-08-16),

4. 11318109 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2022-05-03),

5. 10807777 - Pharmaceutical formulation (2020-10-20),

6. 10799467 - Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy (2020-10-13),

7. 10758514 - Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour (2020-09-01),

8. 10729665 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2020-08-04),

9. 10653641 - Use of cannabinoids in the treatment of mental disorders (2020-05-19),

10. 10538373 - Pharmaceutical formulation (2020-01-21),

11. 10258580 - Cannabinoids for use in the treatment of neurodegenerative diseases or disorders (2019-04-16),

12. 10195159 - Processes and apparatus for extraction of active substances and enriched extracts from natural products (2019-02-05),

13. 10179683 - Pharmaceutical formulation (2019-01-15),

14. 10137095 - Use of cannabinoids in the treatment of epilepsy (2018-11-27),

15. 10111840 - Use of cannabinoids in the treatment of epilepsy (2018-10-30),

GW Pharma Limited is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of cannabinoid prescription medicines. With a focus on harnessing the therapeutic potential of cannabinoids, GW Pharma conducts extensive research and clinical trials to bring innovative treatments to patients. Their products address various medical conditions, including epilepsy, multiple sclerosis, and childhood-onset epilepsy disorders. Headquartered in the United Kingdom, GW Pharma operates globally, improving patients' lives through their commitment to scientific excellence and dedication to providing high-quality and safe medications.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

66 Patents

#14 in Cambridge

#268 in United Kingdom

#10,736 in the World

Cambridge, United Kingdom

Gw Pharma Limited

Forward Citations = 2,521

75 inventors:

Geoffrey W Guy (32 out of 72 patents)

Brian Anthony Whittle (17 out of 28 patents)

Stephen Wright (17 out of 60 patents)

4. Alice Mead (10 out of 12 patents)

5. Colin Stott (9 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…